Global Nucleic Acid-based Drugs Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI10240758

Publication Date:

October 21, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Manufacturing (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

According to this study, the global Nucleic Acid-based Drugs market size will reach US$ million by 2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid-based Drugs market by product type, application, key players and key regions and countries.
Segmentation by product type:
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Segmentation by Application:
Genetic Disease
Cancer
Cardiovascular Diseases
Other
This report also splits the market by region:
United States
China
Europe
Other regions:
Japan
South Korea
Southeast Asia
Rest of world
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleic Acid-based Drugs Market Size 2024-2030
2.1.2 Nucleic Acid-based Drugs Market Size CAGR by Region
2.2 Nucleic Acid-based Drugs Segment by Type
2.2.1 ASO
2.2.2 mRNA
2.2.3 siRNA
2.2.4 miRNA
2.2.5 saRNA
2.2.6 Aptamer
2.3 Nucleic Acid-based Drugs Market Size by Type
2.3.1 Global Nucleic Acid-based Drugs Market Size Market Share by Type (2024-2030)
2.3.2 Global Nucleic Acid-based Drugs Market Size Growth Rate by Type (2024-2030)
2.4 Nucleic Acid-based Drugs Segment by Application
2.4.1 Genetic Disease
2.4.2 Cancer
2.4.3 Cardiovascular Diseases
2.4.4 Other
2.5 Nucleic Acid-based Drugs Market Size by Application
2.5.1 Global Nucleic Acid-based Drugs Market Size Market Share by Application (2024-2030)
2.5.2 Global Nucleic Acid-based Drugs Market Size Growth Rate by Application (2024-2030)
3 Nucleic Acid-based Drugs Key Players
3.1 Date of Key Players Enter into Nucleic Acid-based Drugs
3.2 Key Players Nucleic Acid-based Drugs Product Offered
3.3 Key Players Nucleic Acid-based Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players Nucleic Acid-based Drugs Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 Nucleic Acid-based Drugs by Regions
4.1 Nucleic Acid-based Drugs Market Size by Regions (2024-2030)
4.2 United States Nucleic Acid-based Drugs Market Size Growth (2024-2030)
4.3 China Nucleic Acid-based Drugs Market Size Growth (2024-2030)
4.4 Europe Nucleic Acid-based Drugs Market Size Growth (2024-2030)
4.5 Rest of World Nucleic Acid-based Drugs Market Size Growth (2024-2030)
5 United States
5.1 United States Nucleic Acid-based Drugs Market Size by Type (2024-2030)
5.2 United States Nucleic Acid-based Drugs Market Size by Application (2024-2030)
6 Europe
6.1 Europe Nucleic Acid-based Drugs Market Size by Type (2024-2030)
6.2 Europe Nucleic Acid-based Drugs Market Size by Application (2024-2030)
7 China
7.1 China Nucleic Acid-based Drugs Market Size by Type (2024-2030)
7.2 China Nucleic Acid-based Drugs Market Size by Application (2024-2030)
8 Rest of World
8.1 Rest of World Nucleic Acid-based Drugs Market Size by Type (2024-2030)
8.2 Rest of World Nucleic Acid-based Drugs Market Size by Application (2024-2030)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Key Investors in Nucleic Acid-based Drugs
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 鈥︹€�
11 Key Players Analysis
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Nucleic Acid-based Drugs Product Offered
11.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.1.4 Ionis Pharmaceuticals Main Business Overview
11.1.5 Ionis Pharmaceuticals News
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Nucleic Acid-based Drugs Product Offered
11.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.2.4 Sarepta Therapeutics Main Business Overview
11.2.5 Sarepta Therapeutics News
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Details
11.3.2 Nippon Shinyaku Nucleic Acid-based Drugs Product Offered
11.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.3.4 Nippon Shinyaku Main Business Overview
11.3.5 Nippon Shinyaku News
11.4 BioNTech
11.4.1 BioNTech Company Details
11.4.2 BioNTech Nucleic Acid-based Drugs Product Offered
11.4.3 BioNTech Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.4.4 BioNTech Main Business Overview
11.4.5 BioNTech News
11.5 Moderna Therapeutics
11.5.1 Moderna Therapeutics Company Details
11.5.2 Moderna Therapeutics Nucleic Acid-based Drugs Product Offered
11.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.5.4 Moderna Therapeutics Main Business Overview
11.5.5 Moderna Therapeutics News
11.6 CureVac
11.6.1 CureVac Company Details
11.6.2 CureVac Nucleic Acid-based Drugs Product Offered
11.6.3 CureVac Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.6.4 CureVac Main Business Overview
11.6.5 CureVac News
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Details
11.7.2 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product Offered
11.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.7.4 Alnylam Pharmaceuticals Main Business Overview
11.7.5 Alnylam Pharmaceuticals News
11.8 Regulus Therapeutics
11.8.1 Regulus Therapeutics Company Details
11.8.2 Regulus Therapeutics Nucleic Acid-based Drugs Product Offered
11.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.8.4 Regulus Therapeutics Main Business Overview
11.8.5 Regulus Therapeutics News
11.9 Miragen Therapeutics
11.9.1 Miragen Therapeutics Company Details
11.9.2 Miragen Therapeutics Nucleic Acid-based Drugs Product Offered
11.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.9.4 Miragen Therapeutics Main Business Overview
11.9.5 Miragen Therapeutics News
11.10 Mina Therapeutics
11.10.1 Mina Therapeutics Company Details
11.10.2 Mina Therapeutics Nucleic Acid-based Drugs Product Offered
11.10.3 Mina Therapeutics Nucleic Acid-based Drugs Market Size (2024 VS 2030)
11.10.4 Mina Therapeutics Main Business Overview
11.10.5 Mina Therapeutics News
11.11 NeXstar Pharmaceuticals
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂